Drug Trial Radar · NCT07663630
A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Oct 23, 2026
Primary completion
May 6, 2028
Study completion Jul 1, 2029
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study to investigate the effect of ponsegromab on skeletal muscle mass and physical function in adult participants with non-small cell lung cancer associated cachexia.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Cachexia
Interventions
ponsegromabDrug
Double-Blind ponsegromab Treatment
placeboDrug
Double-Blind placebo Treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in Lumbar Skeletal Muscle IndexTime frame: Baseline, Week 12
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Cancer Care Specialists of Illinois-Decatur
Decatur, Illinois
Decatur Memorial Hospital
Decatur, Illinois
Cancer Care Specialists of Illinois - Cancer Care Center of O'Fallon
O'Fallon, Illinois
Dallas Cancer Specialists
Garland, Texas
Houston Cancer Treatment Centers
Houston, Texas
Lumi Research
Houston, Texas
The Universityof Hong Kong-Shenzhen Hospital
Shenzhen, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.